Skip to main content

Advertisement

SpringerLink
Log in

Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers

  • Review Article
  • Published:
Modern Rheumatology

Abstract

Systemic lupus erythematosus is a chronic, multisystemic, autoimmune disease that may involve the central, peripheral, and autonomic nervous systems and can present with a wide variety of neurological and psychiatric manifestations. In this article, we review the recent literature pertaining to the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). We searched the PUBMED database with no chronological constraints using the following terms: “neuropsychiatric systemic lupus erythematosus” cross-referenced with the terms “pathogenesis” and “biomarkers” for full-text articles in English. The etiology of NPSLE is as yet unknown, though numerous autoantibodies and cytokines have been suggested as possible mediators. Of the numerous autoantibodies and biomarkers examined, anti-phospholipid, anti-ribosomal P, anti-neuronal, anti-glial fibrillary acidic protein (GFAP), anti-endothelial cell, anti-N-methyl-d-aspartate (NMDA), microtubule-associated protein 2 (MAP-2), and matrix metalloproteinase-9 (MMP-9) appear to be elevated in patients with NPSLE. Cytokines that may be involved in the pathology of NPSLE include interleukin (IL)-2, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, and interferons (IFN)-α and -γ. With continued advances in immunological research, new insights into the pathophysiologic mechanisms of NPSLE may lead to the development of biomarkers and new treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Valesini G, Alessandri C, Celestino D, Conti F. Anti-endothelial antibodies and neuropsychiatric systemic lupus erythematosus. Ann NY Acad Sci. 2006;1069:118–28.

    Article  PubMed  CAS  Google Scholar 

  2. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42(4):599–608.

    Google Scholar 

  3. Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol. 2004;31(11):2156–62.

    PubMed  Google Scholar 

  4. Bresnihan B, Hohmeister R, Cutting J, Travers RL, Waldburger M, Black C, et al. The neuropsychiatric disorder in systemic lupus erythematosus: evidence for both vascular and immune mechanisms. Ann Rheum Dis. 1979;38(4):301–6.

    Article  PubMed  CAS  Google Scholar 

  5. Tatsukawa H, Ishii K, Haranaka M, Kumagi M, Hino I, Yoshimatsu H. Evaluation of average amount of cerebral blood flow measured by brain perfusion index in patients with neuropsychiatric systemic lupus erythematosus. Lupus. 2005;14(6):445–9.

    Article  PubMed  CAS  Google Scholar 

  6. Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992;19(5):732–41.

    PubMed  CAS  Google Scholar 

  7. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol. 1988;23(4):380–4.

    Article  PubMed  CAS  Google Scholar 

  8. Greenwood DL, Gitlits VM, Alderuccio F, Sentry JW, Toh BH. Autoantibodies in neuropsychiatric lupus. Autoimmunity. 2002;35(2):79–86.

    Article  PubMed  CAS  Google Scholar 

  9. Zaccagni H, Fried J, Cornell J, Padilla P, Brey RL. Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage. Front Biosci. 2004;9:1654–9.

    Article  PubMed  CAS  Google Scholar 

  10. Asherson RA, Khamashta MA, Gil A, Vazquez JJ, Chan O, Baguley E, et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med. 1989;86(4):391–9.

    Article  PubMed  CAS  Google Scholar 

  11. Trysberg E, Tarkowski A. Cerebral inflammation and degeneration in systemic lupus erythematosus. Curr Opin Rheumatol. 2004;16(5):527–33.

    Article  PubMed  Google Scholar 

  12. Gomez-Pacheco L, Villa AR, Drenkard C, Cabiedes J, Cabral AR, Alarcon-Segovia D. Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med. 1999;106(4):417–23.

    Article  PubMed  CAS  Google Scholar 

  13. Meroni PL, Tincani A, Sepp N, Raschi E, Testoni C, Corsini E, et al. Endothelium and the brain in CNS lupus. Lupus. 2003;12(12):919–28.

    Article  PubMed  CAS  Google Scholar 

  14. Steens SC, Bosma GP, Steup-Beekman GM, le Cessie S, Huizinga TW, van Buchem MA. Association between microscopic brain damage as indicated by magnetization transfer imaging and anticardiolipin antibodies in neuropsychiatric lupus. Arthritis Res Ther. 2006;8(2):R38.

    Article  PubMed  CAS  Google Scholar 

  15. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003;30(5):985–92.

    PubMed  Google Scholar 

  16. Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 1999;42(4):728–34.

    Article  PubMed  CAS  Google Scholar 

  17. Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42(4):735–41.

    Article  PubMed  CAS  Google Scholar 

  18. Conti F, Alessandri C, Bompane D, Bombardieri M, Spinelli FR, Rusconi AC, et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther. 2004;6(4):R366–72.

    Article  PubMed  CAS  Google Scholar 

  19. Elkon KB, Parnassa AP, Foster CL. Lupus autoantibodies target ribosomal P proteins. J Exp Med. 1985;162(2):459–71.

    Article  PubMed  CAS  Google Scholar 

  20. Francoeur AM, Peebles CL, Heckman KJ, Lee JC, Tan EM. Identification of ribosomal protein autoantigens. J Immunol. 1985;135(4):2378–84.

    PubMed  CAS  Google Scholar 

  21. Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med. 1987;317(5):265–71.

    Article  PubMed  CAS  Google Scholar 

  22. West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med. 1995;99(2):153–63.

    Article  PubMed  CAS  Google Scholar 

  23. Watanabe T, Sato T, Uchiumi T, Arakawa M. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: diagnostic and predictive value of longitudinal examination of anti-ribosomal P antibody. Lupus. 1996;5(3):178–83.

    Article  PubMed  CAS  Google Scholar 

  24. Arnett FC, Reveille JD, Moutsopoulos HM, Georgescu L, Elkon KB. Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum. 1996;39(11):1833–9.

    Article  PubMed  CAS  Google Scholar 

  25. Tzioufas AG, Tzortzakis NG, Panou-Pomonis E, Boki KA, Sakarellos-Daitsiotis M, Sakarellos C, et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis. 2000;59(2):99–104.

    Article  PubMed  CAS  Google Scholar 

  26. Nojima Y, Minota S, Yamada A, Takaku F, Aotsuka S, Yokohari R. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992;51(9):1053–5.

    Article  PubMed  CAS  Google Scholar 

  27. Isshi K, Hirohata S. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum. 1998;41(10):1819–27.

    Article  PubMed  CAS  Google Scholar 

  28. Isshi K, Hirohata S. Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1996;39(9):1483–90.

    Article  PubMed  CAS  Google Scholar 

  29. Press J, Palayew K, Laxer RM, Elkon K, Eddy A, Rakoff D, et al. Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum. 1996;39(4):671–6.

    Article  PubMed  CAS  Google Scholar 

  30. Massardo L, Burgos P, Martinez ME, Perez R, Calvo M, Barros J, et al. Antiribosomal P protein antibodies in Chilean SLE patients: no association with renal disease. Lupus. 2002;11(6):379–83.

    Article  PubMed  CAS  Google Scholar 

  31. Yoshio T, Hirata D, Onda K, Nara H, Minota S. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol. 2005;32(1):34–9.

    PubMed  CAS  Google Scholar 

  32. Hirohata S, Arinuma Y, Takayama M, Yoshio T. Association of cerebrospinal fluid anti-ribosomal p protein antibodies with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res Ther. 2007;9(3):R44.

    Article  PubMed  CAS  Google Scholar 

  33. Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med. 1991;90(1):54–62.

    Article  PubMed  CAS  Google Scholar 

  34. Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford). 2002;41(12):1357–66.

    Article  CAS  Google Scholar 

  35. Jonsen A, Bengtsson AA, Nived O, Ryberg B, Truedsson L, Ronnblom L, et al. The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus. 2003;12(11):846–50.

    Article  PubMed  CAS  Google Scholar 

  36. Teh LS, Bedwell AE, Isenberg DA, Gordon C, Emery P, Charles PJ, et al. Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis. 1992;51(4):489–94.

    Article  PubMed  CAS  Google Scholar 

  37. van Dam A, Nossent H, de Jong J, Meilof J, ter Borg EJ, Swaak T, et al. Diagnostic value of antibodies against ribosomal phosphoproteins. A cross sectional and longitudinal study. J Rheumatol. 1991;18(7):1026–34.

    PubMed  Google Scholar 

  38. Sato T, Uchiumi T, Ozawa T, Kikuchi M, Nakano M, Kominami R, et al. Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol. 1991;18(11):1681–4.

    PubMed  CAS  Google Scholar 

  39. Derksen RH, van Dam AP, Gmelig Meyling FH, Bijlsma JW, Smeenk RJ. A prospective study on antiribosomal P proteins in two cases of familial lupus and recurrent psychosis. Ann Rheum Dis. 1990;49(10):779–82.

    Article  PubMed  CAS  Google Scholar 

  40. Karassa FB, Afeltra A, Ambrozic A, Chang DM, De Keyser F, Doria A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 2006;54(1):312–24.

    Article  PubMed  CAS  Google Scholar 

  41. Bluestein HG, Williams GW, Steinberg AD. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med. 1981;70(2):240–6.

    Article  PubMed  CAS  Google Scholar 

  42. Sanna G, Piga M, Terryberry JW, Peltz MT, Giagheddu S, Satta L, et al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus. 2000;9(8):573–83.

    Article  PubMed  CAS  Google Scholar 

  43. Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003;48(10):2881–7.

    Article  PubMed  Google Scholar 

  44. Alessandri C, Conti F, Valesini G. Role of anti-glial fibrillary acidic protein antibodies in the pathogenesis of neuropsychiatric systemic lupus erythematosus should be clarified: comment on the article by Trysberg et al. Arthritis Rheum. 2004;50(5):1698–9. author reply 1699.

    Article  PubMed  Google Scholar 

  45. Yoshio T, Masuyama J, Kano S. Antiribosomal P0 protein antibodies react with the surface of human umbilical vein endothelial cells. J Rheumatol. 1996;23(7):1311–2.

    PubMed  CAS  Google Scholar 

  46. Yoshio T, Masuyama J, Ikeda M, Tamai K, Hachiya T, Emori T, et al. Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. J Rheumatol. 1995;22(9):1681–7.

    PubMed  CAS  Google Scholar 

  47. Song J, Park YB, Lee WK, Lee KH, Lee SK. Clinical associations of anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Rheumatol Int. 2000;20(1):1–7.

    Article  PubMed  CAS  Google Scholar 

  48. Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature. 1986;319(6056):774–6.

    Article  PubMed  CAS  Google Scholar 

  49. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330(9):613–22.

    Article  PubMed  CAS  Google Scholar 

  50. Skerry TM, Genever PG. Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci. 2001;22(4):174–81.

    Article  PubMed  CAS  Google Scholar 

  51. Zipfel GJ, Lee JM, Choi DW. Reducing calcium overload in the ischemic brain. N Engl J Med. 1999;341(20):1543–4.

    Article  PubMed  CAS  Google Scholar 

  52. Cavalheiro EA, Olney JW. Glutamate antagonists: deadly liaisons with cancer. Proc Natl Acad Sci USA. 2001;98(11):5947–8.

    Article  PubMed  CAS  Google Scholar 

  53. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 1990;13:171–82.

    Article  PubMed  CAS  Google Scholar 

  54. Dubinsky JM, Rothman SM. Intracellular calcium concentrations during “chemical hypoxia” and excitotoxic neuronal injury. J Neurosci. 1991;11(8):2545–51.

    PubMed  CAS  Google Scholar 

  55. Kotzin BL, Kozora E. Anti-DNA meets NMDA in neuropsychiatric lupus. Nat Med. 2001;7(11):1175–6.

    Article  PubMed  CAS  Google Scholar 

  56. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med. 2001;7(11):1189–93.

    Article  PubMed  CAS  Google Scholar 

  57. Ozawa S, Kamiya H, Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol. 1998;54(5):581–618.

    Article  PubMed  CAS  Google Scholar 

  58. Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA. 2006;103(52):19854–9.

    Article  PubMed  CAS  Google Scholar 

  59. Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008;58(4):1130–5.

    Article  PubMed  CAS  Google Scholar 

  60. Omdal R, Brokstad K, Waterloo K, Koldingsnes W, Jonsson R, Mellgren SI. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol. 2005;12(5):392–8.

    Article  PubMed  CAS  Google Scholar 

  61. Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002;95(1):114–8. table of contents.

    Article  PubMed  CAS  Google Scholar 

  62. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.

    Article  PubMed  CAS  Google Scholar 

  63. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2505–14.

    Article  PubMed  CAS  Google Scholar 

  64. Husebye ES, Sthoeger ZM, Dayan M, Zinger H, Elbirt D, Levite M, et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64(8):1210–3.

    Article  PubMed  CAS  Google Scholar 

  65. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol. 1996;156(1):1–4.

    PubMed  CAS  Google Scholar 

  66. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol. 2006;26(4):299–307.

    Article  PubMed  CAS  Google Scholar 

  67. Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol. 2002;127(2):393–8.

    Article  PubMed  CAS  Google Scholar 

  68. Ainiala H, Hietaharju A, Dastidar P, Loukkola J, Lehtimaki T, Peltola J, et al. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum. 2004;50(3):858–65.

    Article  PubMed  CAS  Google Scholar 

  69. Trysberg E, Blennow K, Zachrisson O, Tarkowski A. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther. 2004;6(6):R551–6.

    Article  PubMed  CAS  Google Scholar 

  70. Williams RC Jr., Sugiura K, Tan EM. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2004;50(4):1239–47.

    Article  PubMed  CAS  Google Scholar 

  71. Lefranc D, Launay D, Dubucquoi S, de Seze J, Dussart P, Vermersch M, et al. Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. Arthritis Rheum. 2007;56(10):3420–32.

    Article  PubMed  CAS  Google Scholar 

  72. Jara LJ, Irigoyen L, Ortiz MJ, Zazueta B, Bravo G, Espinoza LR. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol. 1998;17(2):110–4.

    Article  PubMed  CAS  Google Scholar 

  73. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 1990;33(5):644–9.

    Article  PubMed  CAS  Google Scholar 

  74. Hirohata S, Hayakawa K. Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1999;42(12):2729–30.

    Article  PubMed  CAS  Google Scholar 

  75. Winfield JB, Shaw M, Silverman LM, Eisenberg RA, Wilson HA 3rd, Koffler D. Intrathecal IgG synthesis and blood–brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med. 1983;74(5):837–44.

    Article  PubMed  CAS  Google Scholar 

  76. Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus. 1992;1(2):111–7.

    Article  PubMed  CAS  Google Scholar 

  77. Tsai CY, Wu TH, Tsai ST, Chen KH, Thajeb P, Lin WM, et al. Cerebrospinal fluid interleukin-6, prostaglandin E2 and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections. Scand J Rheumatol. 1994;23(2):57–63.

    Article  PubMed  CAS  Google Scholar 

  78. Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus. 2000;9(7):498–503.

    Article  PubMed  CAS  Google Scholar 

  79. Dellalibera-Joviliano R, Dos Reis ML, Cunha Fde Q, Donadi EA. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J Rheumatol. 2003;30(3):485–92.

    PubMed  CAS  Google Scholar 

  80. Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A, Davila-Maldonado L, Atisha-Fregoso Y, Llorente L, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007;56(4):1242–50.

    Article  PubMed  CAS  Google Scholar 

  81. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum. 1992;35(4):417–22.

    Article  PubMed  CAS  Google Scholar 

  82. Svenungsson E, Andersson M, Brundin L, van Vollenhoven R, Khademi M, Tarkowski A, et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis. 2001;60(4):372–9.

    Article  PubMed  CAS  Google Scholar 

  83. Gilad R, Lampl Y, Eshel Y, Barak V, Sarova-Pinhas I. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol. 1997;36(2):190–3.

    Article  PubMed  CAS  Google Scholar 

  84. Santer DM, Yoshio T, Minota S, Moller T, Elkon KB. Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol. 2009;182(2):1192–201.

    PubMed  CAS  Google Scholar 

  85. Hanly JG, Harrison MJ. Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol. 2005;19(5):799–821.

    Article  PubMed  Google Scholar 

  86. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332(15):993–7.

    Article  PubMed  CAS  Google Scholar 

  87. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195–205.

    Article  PubMed  CAS  Google Scholar 

  88. Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des. 2008;14(13):1261–9.

    PubMed  CAS  Google Scholar 

  89. Valesini G, Priori R, Francia A, Balestrieri G, Tincani A, Airo P, et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol. 1994;16(2–3):313–21.

    PubMed  CAS  Google Scholar 

  90. Milstone AM, Meyers K, Elia J. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol. 2005;24(4):394–7.

    Article  PubMed  Google Scholar 

  91. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol. 1992;10(4):391–3.

    PubMed  CAS  Google Scholar 

  92. Sherer Y, Levy Y, Langevitz P, Lorber M, Fabrizzi F, Shoenfeld Y. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol. 1999;18(2):170–3.

    Article  PubMed  CAS  Google Scholar 

  93. Traynor AE, Barr WG, Rosa RM, Rodriguez J, Oyama Y, Baker S, et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum. 2002;46(11):2917–23.

    Article  PubMed  Google Scholar 

  94. Lehnhardt FG, Scheid C, Holtik U, Burghaus L, Neveling M, Impekoven P, et al. Autologous blood stem cell transplantation in refractory systemic lupus erythematodes with recurrent longitudinal myelitis and cerebral infarction. Lupus. 2006;15(4):240–3.

    Article  PubMed  CAS  Google Scholar 

  95. Gorman C, Leandro M, Isenberg D. Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus? Lupus. 2004;13(5):312–6.

    Article  PubMed  CAS  Google Scholar 

  96. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580–9.

    Article  PubMed  CAS  Google Scholar 

  97. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50(11):3580–90.

    Article  PubMed  CAS  Google Scholar 

  98. Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford). 2005;44(2):176–82.

    Article  CAS  Google Scholar 

  99. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46(10):2673–7.

    Article  PubMed  Google Scholar 

  100. Neuwelt CM, Young RG, McGhee RA, Freeman J. Role of rituximab in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus as monotherapy or in combination therapy. Ann Rheum Dis. 2005;64(Suppl III):57.

    Google Scholar 

  101. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470–5.

    Article  PubMed  CAS  Google Scholar 

  102. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hara M, Kubota T, et al. Efficacy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. Ann Rheum Dis. 2006;65(Suppl II):197.

    Google Scholar 

  103. Hillen N, Stevanovic S. Contribution of mass spectrometry-based proteomics to immunology. Expert Rev Proteomics. 2006;3(6):653–64.

    Article  PubMed  CAS  Google Scholar 

  104. Hofstadler SA, Severs JC, Smith RD, Swanek FD, Ewing AG. Analysis of single cells with capillary electrophoresis electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom. 1996;10(8):919–22.

    Article  PubMed  CAS  Google Scholar 

  105. Rood MJ, Keijsers V, van der Linden MW, Tong TQ, Borggreve SE, Verweij CL, et al. Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann Rheum Dis. 1999;58(2):85–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Rheumatology Division, Lincoln Medical and Mental Health Center, 234 E. 149th Street, New York, NY, 10451, USA

    Petros Efthimiou

  2. Department of Medicine, Weill Cornell Medical College, New York, NY, USA

    Petros Efthimiou

  3. UCLA Department of Family Medicine, Les Kelley Family Health Center, 1920 Colorado Avenue, Santa Monica, CA, 90404, USA

    Michelle Blanco

Authors
  1. Petros Efthimiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle Blanco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Petros Efthimiou.

About this article

Cite this article

Efthimiou, P., Blanco, M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod Rheumatol 19, 457–468 (2009). https://doi.org/10.1007/s10165-009-0198-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-009-0198-5

Keywords

Search

Navigation